跳至主導覽
跳至搜尋
跳過主要內容
國立成功大學 首頁
English
中文
首頁
概要
研究單位
研究成果
專案
學生論文
設備
獎項
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
賴 嘉鎮
教授
藥學系
電子郵件
edward_lai
mail.ncku.edu
tw
h-index
4075
引文
30
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2013
2025
每年研究成果
概覽
指紋
網路
專案
(10)
研究成果
(170)
類似的個人檔案
(6)
監製作品
(5)
指紋
查看啟用 Edward Lai 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
100%
sodium glucose cotransporter-2 inhibitors
42%
Non Insulin Dependent Diabetes Mellitus
38%
Cerebrovascular Accident
38%
Antipsychotic
29%
Glucagon Like Peptide 1 Receptor Agonist
27%
Denosumab
27%
Tumor Necrosis Factor Inhibitor
18%
Anticoagulant Agent
18%
Atrial Fibrillation
18%
Prevalence
16%
Sodium Glucose Cotransporter 2 Inhibitor
15%
Brain Ischemia
15%
Congestive Heart Failure
14%
Observational Study
14%
Adverse Drug Reaction
14%
Hip Fracture
13%
Hypotension
13%
Hemodialysis
13%
Antihypertensive
13%
Ischemic Heart Disease
12%
Randomized Controlled Trial
12%
Ranibizumab
12%
Aflibercept
12%
Diabetic Macular Edema
11%
Rheumatoid Arthritis
10%
Inflammatory Arthritis
10%
Comorbidity
10%
Chronic Kidney Failure
9%
Warfarin
9%
Disease Modifying Antirheumatic Drug
9%
Medication Error
9%
Hydrochlorothiazide
9%
Case-Control Study
9%
Pharmacoepidemiology
9%
Isoniazid
9%
Thromboembolism
9%
Latent Tuberculosis
9%
Diseases
8%
Adverse Event
8%
Dapagliflozin
8%
Antivitamin K
7%
Antidepressant
7%
All Cause Mortality
7%
Clinical Trial
7%
Thyroxine
7%
Prostate Cancer
6%
Ustekinumab
6%
Secukinumab
6%
Dutasteride
6%
Medicine and Dentistry
Cohort Analysis
38%
Hazard Ratio
27%
Retrospective Cohort Study
25%
Sodium Glucose Cotransporter 2 Inhibitor
24%
Maturity Onset Diabetes of the Young
24%
Glucagon-Like Peptide-1 Agonist
15%
Meta-Analysis
14%
Electronic Patient Record
13%
Patient with Type 2 Diabetes
12%
Prevalence
11%
Systematic Review
10%
Cohort Effect
10%
Proportional Hazards Model
10%
Inflammatory Arthritis
10%
Rheumatoid Arthritis
10%
Diagnosis Code
9%
Atrial Fibrillation
9%
Acetylcholinesterase Inhibitor
9%
Blood Clotting Factor
9%
Cotransporter
9%
Disease Modifying Antirheumatic Drug
9%
TNF Inhibitor
9%
Denosumab
8%
Diseases
8%
Zoledronic Acid
7%
Comorbidity
7%
Randomized Controlled Trial
6%
Odds Ratio
6%
Ischemic Heart Disease
5%
Decision Making
5%
Statin
5%
Alanine Aminotransferase
5%
Cardiovascular Risk
5%
Myositis
5%
Drug Safety
5%
Antipsychotic Drug
5%
Congestive Heart Failure
5%
Health Care
5%
Brain Ischemia
5%
Dipeptidyl Peptidase-4 Inhibitor
5%
Medicine
5%
Adverse Drug Reaction
5%
Keyphrases
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
27%
Taiwan
25%
Target Trial Emulation
20%
Hazard Ratio
19%
Type 2 Diabetes Mellitus (T2DM)
16%
Confidence Interval
16%
Type 2 Diabetic Patients
16%
Receptor Agonist
14%
Multi-institutional
14%
A1 Receptor
14%
Glucagon-like
14%
Retrospective Cohort Study
12%
Emulation Framework
10%
Atrial Fibrillation
9%
Population-based Study
9%
Chronic Kidney Disease
9%
Coagulation Factor Replacement Therapy
9%
Nested Case-control Study
9%
Latent Tuberculosis
9%
Isoniazid Prophylaxis
9%
Non-vitamin K Antagonist Oral Anticoagulants
9%
Diabetic Macular Edema
9%
TriNetX
8%
Propensity Score Matching
7%
Dementia Risk
7%
Secukinumab
6%
Incidence Rate
6%
Warfarin
6%
Glucagon-like peptide-1 (GLP-1)
5%
Glucagon-like peptide-1 Receptor (GLP-1R)
5%
Chang Gung Research Database
5%
Mortality Risk
5%
Electronic Health Record Databases
5%
Idiopathic Inflammatory Myositis
5%
Bleeding Risk
5%
